AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMT-676’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMT-676 overview
AMT-676 is under development for the treatment of colorectal cancer, gastric cancer, esophageal adenocarcinoma, cholangiocarcinoma, pancreatic ductal cancers, neuroendocrine tumors and unspecified cancer. The drug candidate is an antibody-drug conjugate and is being developed based on MabArrayTM technology.
It was also under development for gastric cancer, colorectal cancer and pancreatic cancer.
Multitude therapeutics overview
Multitude therapeutics Inc is a Pharmaceuticals and Healthcare company that Develop antibody-drug conjugates. The company is headquartered in Los Angles, California, The U.S.
For a complete picture of AMT-676’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.